QFRD targets S&P 500 companies that generate strong free cash flow while maintaining high R&D spending — essentially profitable innovators who can fund growth internally. This dual screen aims to capture firms with both current profitability and future growth potential, avoiding the typical growth vs. value tradeoff.
How It Works
The fund screens S&P 500 constituents for companies ranking in the top quintile for both free cash flow generation and R&D intensity relative to revenues. This creates a concentrated portfolio of roughly 50-100 names that are weighted by a composite score combining FCF yield and R&D spending ratio. The index rebalances quarterly to capture shifts in cash generation and R&D priorities, with sector caps to prevent overconcentration in tech or pharma.
Key Features
- Combines cash generation with innovation spending — rare quality screen that values both present and future
- Quarterly rebalancing captures R&D cycle shifts faster than annual quality funds
- Zero expense ratio makes this cheaper than any actively managed innovation strategy
Risks
- R&D spending can destroy value — high R&D doesn't guarantee successful products, could underperform simple FCF screens by 5-10% annually
- Sector concentration risk — likely 40-60% in tech/healthcare where R&D matters most, amplifying drawdowns
- Brand new fund with no track record — strategy sounds good on paper but unproven in practice
Who Should Own This
Best suited for growth-oriented investors who want exposure to innovation but are tired of paying 50x sales for unprofitable tech darlings. Works as a core equity replacement for those seeking quality with a growth tilt, or as a 10-20% satellite to add R&D exposure without abandoning valuation discipline. The zero expense ratio makes it particularly attractive for long-term holders who believe innovation drives returns but want companies that can self-fund their research.